Skip to main content
SpringerLink
Log in

Opioids in the Etiology and Treatment of Psychiatric Disorders

  • Chapter
Opioids II

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 104 / 2))

Abstract

Very few discoveries in the neurosciences have stimulated clinical speculation and experimentation regarding the etiology of psychiatric illness to the same extent as have the identification of the opiate receptor(s) and the isolation of endogenous morphine-like ligands. The well-known psychotropic properties of opiates and in particular the psychotomimetic effects of some mixed opiate antagonists/agonists (Musacchio 1990; Pfeiffer et al. 1986), the regional brain distribution of opioids and their receptors (Goldstein 1976), and the behavioral effects of opioid peptides administered into the cerebrospinal fluid (CSF) or into the periaqueductal gray of rats (Bloom et al. 1976; Jaquet and Marks 1976) all suggest that dysfunction of opioidergic systems may be associated with psychiatric symptomatology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agren H, Terenius L (1983) Depression and CSF endorphin fraction: I. Seasonal variation and higher levels in unipolar than bipolar patients. Psychiatry Res 10:303–311

    PubMed  CAS  Google Scholar 

  • Alexopoulos GS, Inturrisi CE, Lipman R, Frances R, Haycox J, Dougherty JH, Rossier J (1983) Plasma immunoreactive β-endorphin levels in depression. Effects of electroconvulsive therapy. Arch Gen Psychiatry 40:181–183

    PubMed  CAS  Google Scholar 

  • Atkinson RL (1982) Naloxone decreases food intake in obese humans. J Clin Endocrinol Metab 55:196–198

    PubMed  CAS  Google Scholar 

  • Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL (1985) Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 38:419–422

    PubMed  CAS  Google Scholar 

  • Ball R, Howlett T, Silverstone T, Rees L (1987) The interrelationship of betaendorphin, ACTH and cortisol in depressive illness: a controlled study. Psychol Med 17:31–37

    PubMed  CAS  Google Scholar 

  • Banki CM, Arato M (1987) Multiple hormonal responses to morphine: relationship to diagnosis and dexamethasone suppression. Psychoneuroendocrinology 12:3–11

    PubMed  CAS  Google Scholar 

  • Berger PA, Watson SJ, Akil H, Ellicot GR, Rubin RT, Pfefferbaum A, Davis KL, Barchas JD, Li CH (1980) β-Endorphin and schizophrenia. Arch Gen Psychiatry 37:635–640

    Google Scholar 

  • Berger PA, Watson SJ, Akil H, Barchas JD (1981) The effects of naloxone in chronic schizophrenia. Am J Psychiatry 138:913–918

    PubMed  CAS  Google Scholar 

  • Berrettini WH, Nurnberger JI, Chan JSD, Chrousos GP, Gaspar L, Gold PW, Seidah NG, Simmons-Alling S, Goldin LR, Chrétien M, Gershon ES (1985) Pro-opiome1anocortin-re1ated peptides in cerebrospinal fluid: a study of manicdepressive disorder. Psychiatry Res 16:287–302

    PubMed  CAS  Google Scholar 

  • Black PM, Ballantine HT, Carr DB, Beal MF, Martin JB (1986) Beta-endorphin and somatostatin concentration in the ventricular cerebrospinal fluid of patients with affective disorder. Biol Psychiatry 21:1075–1077

    Google Scholar 

  • Bloom F, Segal D, Ling N, Guillemin R (1976) Endorphins. Profound behavioural effects in rats suggest new etiological factors in mental illness. Science 193: 1081–1083

    Google Scholar 

  • Blum K, Nisipeanu PF, Roberts E (1987) Naloxone in tardive dyskinesia Psychopharmacology 93:538

    CAS  Google Scholar 

  • Brambilla F, Genazzani AR, Facchinetti F, Parrini D, Petraglia F, Sacchetti E, Scarone S, Guastalla A, D’antona N (1981) β-Endorphin and β-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders. Psychoneuroendocrinology 6:321–330

    PubMed  CAS  Google Scholar 

  • Brambilla F, Facchinetti F, Petraglia F, Vanzulli L, Genazzani AR (1984) Secretion pattern of endogenous opioids in chronic schizophrenia. Am J Psychiatry 141:1183–1189

    PubMed  CAS  Google Scholar 

  • Brambilla F, Cavagnini F, Invitti C, Poterzio F, Lampertico M, Sali L, Maggioni M, Candolfi C, Panerai A, Müller EE (1985) Neuroendocrine and psychopathological indices in anorexia nervosa: resemblance to primary affective disorder. Psychiatry Res 16:165–171

    PubMed  CAS  Google Scholar 

  • Brambilla F, Facchinetti F, Petraglia F, Smeraldi E, Bellodi L, Brancato V, Genazzani AR (1987) Effects of neuroleptic treatment on peripheral opioid secretion. Neuropsychobiology 18:68–73

    PubMed  CAS  Google Scholar 

  • Brizer DA, Hartman N, Sweeney J, Millman RB (1985) Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 142:1106–1107

    PubMed  CAS  Google Scholar 

  • Burbach JPH, Loeber JG, Verhoef J, De Kloet ER, van Ree JM, De Wied D (1979) Schizophrenia and degradation of endorphins in cerebrospinal fluid. Lancet 11:480

    Google Scholar 

  • Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC (1990) Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 26: 130–135

    PubMed  CAS  Google Scholar 

  • Carpenter WT Jr, Sadler JH, Light PD, Hanlon TE, Kurland AA, Penna MW, Reed WP, Wilkinson EH, Barko JJ (1983) The therapeutic efficacy of hemodialysis in schizophrenia. N Engl J Med 308:669–675

    PubMed  Google Scholar 

  • Cohen MR, Cohen RM, Pickar D, Weingartner H, Murphy DL (1983) High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal and physiological responses. Arch Gen Psychiatry 40:613–619

    PubMed  CAS  Google Scholar 

  • Cohen MR, Cohen RM, Pickar D, Sunderland T, Mueller EA, Murphy DL (1984a) High dose naloxone in depression. Biol Psychiatry 19:825–832

    PubMed  CAS  Google Scholar 

  • Cohen MR, Pickar D, Extein I, Gold MS, Sweeney DR (1984b) Plasma cortisol and β-endorphin immunoreactivity in non-major and major depression. Am J Psychiatry 141:628–632

    PubMed  CAS  Google Scholar 

  • Cohen MR, Pickar D, Cohen RM (1985) High-dose naloxone administration in chronic schizophrenia. Biol Psychiatry 20:570–583

    Google Scholar 

  • Coid J, Allolio B, Rees LH (1983) Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 11:545–546

    Google Scholar 

  • Dager SR, Cowley DS, Dorsa DM, Dunner DL (1989) Plasma beta-endorphin response to lactate infusion. Biol Psychiatry 25:243–245

    PubMed  CAS  Google Scholar 

  • Daly RJ, Duggan PF, Bracken PJ, Doonan HJ, Kelleher NJ (1987) Plasma levels of β-endorphin in depressed patients with and without pain. Br J Psychiatry 150:224–227

    PubMed  CAS  Google Scholar 

  • Davis GC, Bunney WE, DeFraites EG, Kleinman JE, van Kammen DP, Post RM, Wyatt RJ (1977) Intravenous naloxone administration in schizophrenia and affective illness. Science 197:74–77

    PubMed  CAS  Google Scholar 

  • Davis TP, Culling-Berglund AJ, Schoemaker H (1986) Specific regional differences of in vitro β-endorphin metabolism in schizophrenics. Life Sci 39:2601–2609

    PubMed  CAS  Google Scholar 

  • Drago F, Wiegant VM, Sapienza G, Aguglia E, Rapisarda V, Scapagnini U (1982) Mianserin reduces plasma levels of β-endorphin immunoreactivity in depressed patients. Experentia 38:685–686

    CAS  Google Scholar 

  • Dupont A, Villeneuve A, Bouchard JP, Bouchard R, Merand V, Rouleau D, Labrie F (1978) Rapid inactivation of enkephaline-like material by CSF in chronic schizophrenia. Lancet 11:1107

    Google Scholar 

  • Emrich HM, Cording C, Piree S, Kölling A, von Zerssen D, Herz A (1977) Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmacopsychiatry 10:265–270

    CAS  Google Scholar 

  • Emrich HM, Höllt V, Kissling W, Fischler M, Laspe H, Heinemann H, von Zerssen D, Herz A (1979) β-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmacopsychiatry 12:269–276

    CAS  Google Scholar 

  • Emrich HM, Zaudig M, von Zerssen D, Kissling W, Dirlich G, Herz A (1981) Action of (des-tyr)-γ-endorphin in schizophrenia. In: Emrich HM (ed) The role of endorphins in neuropsychiatry. Karger, Basel, pp 279–286

    Google Scholar 

  • Emrich HM, Vogt P, Herz A, Kissling W (1982) Antidepressant effects of buprenorphine. Lancet II:709

    Google Scholar 

  • Extein I, Pottash ALC, Gold MS, Sweeney DR, Martin DM, Goodwin FK (1980) Deficient prolactin response to morphine in depressed patients. Am J Psychiatry 137:845–846

    PubMed  CAS  Google Scholar 

  • Extein I, Pickar D, Gold MS, Gold PW, Pottasch ALC, Sweeney DR, Ross RJ, Rebard R, Martin D, Goodwin FK (1981a) Methadone and morphine in depression. Psychopharmacol Bull 17:29–33

    PubMed  CAS  Google Scholar 

  • Extein I, Pottash ALC, Gold MS, Anniti W (1981b) Cortisol response to naloxone in depressed patients and controls. Neuroendocrinol Lett 3:121

    Google Scholar 

  • Facchinetti F, Nappi G, Storchi R, Scelsi M, Sances G, Petraglia F, Genazzani AR (1985) Abnormal pro-opiomelanocortin processing in Alzheimer disease. J Neurochem 44 (Suppl):192–195

    Google Scholar 

  • Facchinetti F, Martignoni E, Petraglia F, Sances MG, Nappi G, Genazzani AR (1987) Premenstrual fall of plasma-B-endorphin in patients with premenstrual syndrome. Fertil Steril 47:570–573

    PubMed  CAS  Google Scholar 

  • File SE, Silverstone TS (1981) Naloxone changes self-ratings but not performance in normal subjects. Psychopharmacology 74:353–354

    PubMed  CAS  Google Scholar 

  • Frecska E, Arato M, Banki CM, Mohari K, Perenyi A, Bagdy G, Fekete MIK (1989) Prolactin response to fentanyl in depression. Biol Psychiatry 25:692–696

    PubMed  CAS  Google Scholar 

  • Freeman CPL, Fairburn CG (1981) Lack of effect of naloxone and schizophrenic auditory hallucinations. Psychol Med 11:405–407

    PubMed  CAS  Google Scholar 

  • Genazzani AR, Petraglia F, Facchinetti F, Monittola C, Scarone S, Brambilla F (1984) Opioid plasma levels in primary affective disorders. Neuropsychobiology 12:78–85

    PubMed  CAS  Google Scholar 

  • Gerner RH, Sharp B (1982) CSF B-endorphin-immunoreactivity in normal, schizophrenic, depressed, manic and anorexic subjects. Brain Res 237:244–247

    PubMed  CAS  Google Scholar 

  • Gerner RH, Catlin DH, Gorelick DA, Hui KK, Li CH (1980) β-Endorphin. Intravenous infusion causes behavioral change in psychiatric patients. Arch Gen Psychiatry 37:642–647

    PubMed  CAS  Google Scholar 

  • Ghadirian AM, Gianoulakis C, Nair NPV (1988) The effect of electroconvulsive therapy on endorphins in depression. Biol Psychiatry 23:459–464

    PubMed  CAS  Google Scholar 

  • Gil-Ad I, Dickerman Z, Amdursky S, Laron Z (1986) Diurnal rhythm of plasma beta-endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects. Psychopharmacology 88:496–499

    PubMed  CAS  Google Scholar 

  • Gillberg C, Terenius L, Lonnerholm G (1985) Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arch Gen Psychiatry 42:780–783

    PubMed  CAS  Google Scholar 

  • Gillman MA, Sandyk R (1985) Tourette syndrome and the opioid system. Psychiatry Res 15:161–162

    PubMed  CAS  Google Scholar 

  • Gispen-de-Wied CC, Westenberg HGM, Thijssen JHH, van Ree JM (1987) The dexamethasone and cortisol suppression test in depression: B-endorphin as a useful marker. Psychoneuroendocrinology 12:355–366

    PubMed  CAS  Google Scholar 

  • Gitlin MJ, Gerner RH, Rosenblatt M (1981) Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology 74:51–53

    PubMed  CAS  Google Scholar 

  • Goldstein A (1976) Opioid peptides (endorphins) in pituitary and brain. Science, 193:1081

    PubMed  CAS  Google Scholar 

  • Grevert P, Albert LH, Inturrisi CE, Goldstein A (1983) Effects of eight-hour naloxone infusions on human subjects. Biol Psychiatry 18: 1375–1392

    PubMed  CAS  Google Scholar 

  • Gunne LM, Lindström L, Terenius L (1977) Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm 40:13–19

    PubMed  CAS  Google Scholar 

  • Hamilton JA, Gallant SA (1988) Premenstrual symptom changes and plasma Bendorphin B-lipotropin throughout the mentrual cycle. Psychoneuroendocrinology 13:505–514

    PubMed  CAS  Google Scholar 

  • Hameroff SR, Cork RC, Scherer K, Crago BR, Neuman C, Womble JR, Davis TP (1982) Doxepin effects on chronic pain, depression and plasma opioids. J Clin Psychiatry 43:22–26

    PubMed  CAS  Google Scholar 

  • Hatsukami DK, Mitchell JE, Morlex JE, Morgan SF, Levine AS (1986) Effect of naltrexone on mood and cognitive functioning among overweight men. Biol Psychiatry 21:293–300

    PubMed  CAS  Google Scholar 

  • Herman BH, Hammock MK, Arthur-Smith A, Egan J, Chatoor I, Zelnik N, Corradine M, Applegate K, Boeckx RL, Sharp SD (1986) Role of opioid peptides in autism. Effects of acute administration of naltrexone. Soc Neurosci 12:1172

    Google Scholar 

  • Herman BH, Hammock MK, Arthur-Smith A, Egan J, Chatoor I, Werner A, Zelnik N (1987) Naltrexone decreases self-injurious behavior. Ann Neurol 22:550–552

    PubMed  CAS  Google Scholar 

  • Hoehn-Saric R, Masek BJ (1981) Effects of naloxone on normals and chronically anxious patients. Biol Psychiatry 16: 1041–1050

    PubMed  CAS  Google Scholar 

  • Hunt DD, Adamson R, Egan K, Carr JE (1988) Opioids: mediators of fear or mania? Biol Psychiatry 23:426–428

    PubMed  CAS  Google Scholar 

  • Insel TR, Pickar D (1983) Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 140:1219–1220

    PubMed  CAS  Google Scholar 

  • Janal MN, Colt EWD, Clark WC, Glusman M (1984) Pain sensitivity and plasma endocrine levels in man following long-distance running: effects of naloxone. Pain 19:13–25

    PubMed  CAS  Google Scholar 

  • Janowsky DS, Segal DS, Bloom F, Abrams A, Guillemin R (1977) Lack of effect of naloxone on schizophrenic symptoms. Am J Psychiatry 134:926–927

    PubMed  CAS  Google Scholar 

  • Jaquet YF, Marks N (1976) The C-fragment of β-lipotropin: an endogenous neuroleptic or antipsychotogen? Science 194:632

    Google Scholar 

  • Joergensen A, Fog R (1986) Enkephalin analogue in schizophrenia. Double blind cross-over trial. Acta Psychiatr Scand 73:45–48

    PubMed  CAS  Google Scholar 

  • Jolkkonen JT, Soininen HS, Riekkinen PJ (1984) β-Endorphin-like immunoreactivity in CSF of patients with Alzheimer’s disease. Acta Neurol Scand Suppl 98:234–235

    Google Scholar 

  • Jonas JM, Gold MS (1986) Naltrexone reverses bulimic symptoms. Lancet 1:807

    PubMed  CAS  Google Scholar 

  • Judd LL, Janowsky DS, Segal DS, Parker DS, Huey LY (1981a) Behavioral effects of methadone in schizophrenic patients. Am J Psychiatry 138:243–345

    PubMed  CAS  Google Scholar 

  • Judd LL, Janowsky DS, Zettner A, Huey LY, Takahashi KI (1981b) Effects of naloxone-HCI on cortisol levels in patients with affective disorder and normal controls. Psychiatry Res 4:277–283

    PubMed  CAS  Google Scholar 

  • Judd LL, Risch SC, Parker DC, Janowsky DS, Segal DS, Huey LY (1982) Blunted prolactin response. A neuroendocrine abnormality manifested by depressed patients. Arch Gen Psychiatry 39:1413–1416

    PubMed  CAS  Google Scholar 

  • Jungkunz G, Nedopil N, Ruther E (1983) Acute effects of the synthetic analogue of methionine enkephalin FK 33–824 on depressive symptoms. Pharmacopsychiatry 16:90–92

    CAS  Google Scholar 

  • Kärkkäinen J, Laatikainen T, Naukkarinen H, Salminen K, Spoov J, Stenman UH, Rimon R (1987) Plasma endogenous opioids and dexamethasone suppression test in depression. Psychiatry Res 21:151–159

    PubMed  Google Scholar 

  • Kars H, Broekema W, Glaudemans-van-Gelderen I, Verhoeven WMA, Van Ree JM (1990) Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psychiatry 27:741–746

    PubMed  CAS  Google Scholar 

  • Kaye WH, Berrettini WH, Gwirtsman HE, Chretien M, Gold PW, George DT, Jimerson DC, Ebert MH (1987) Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including β-endorphin) in anorexia nervosa. Life Sci 41:2147–2155

    PubMed  CAS  Google Scholar 

  • Kleinman JE, Hong J, Iadarola M, Govoni S, Gillin CJ (1985) Neuropeptides in human brains. Post-mortem studies. Prog Neuropsychopharmacol Biol Psychiatry 9:91–95

    PubMed  CAS  Google Scholar 

  • Kline NN, Li CH, Lehman HE, Lathja A, Laski E, Cooper T (1977) β-Endorphininduced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34:1111–1113

    PubMed  CAS  Google Scholar 

  • Kumor KM, Haertzen CA, Jasinski DR, Johnson RE (1987) The psychopharmaco~ logic and prolactin response after large doses of naloxone in man. Pharmacol Biochem Behav 30:967–975

    Google Scholar 

  • Kurland AA, Maccabe OL, Hanlon TE, Sullivan D (1977) The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride. Am J Psychiatry 134:1408–1410

    PubMed  CAS  Google Scholar 

  • Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, Bissette G, Nemeroff CB, Goodman WK, Cohen DJ (1988) Elevated CSF dynorphin A (1–8) in Tourette’s syndrome. Life Sci 43:2015–2023

    PubMed  CAS  Google Scholar 

  • Lehman HE, Ananth JV, Geagea KC, Ban TA (1971) Treatment of depression with dexedrine and demerol. Curr Ther Res Clin Exp 13:42–49

    Google Scholar 

  • Lienemann J, Walker F (1989) Naltrexone for treatment of self-injury. Am J Psychiatry 146:639–640

    Google Scholar 

  • Lin S-C, Maruta T, Newman DC, Kao PC (1986) Plasma levels of cortisol, corticotropin, and β-endorphin in patients with major depression. J Clin Psychiatry 47:413–414

    PubMed  CAS  Google Scholar 

  • Lindenmayer J-P, Gardner E, Goldberg E, Opler LA, Kay SR, Van Praag HM, Weiner M, Zukin S (1988) High-dose naloxone in tardive dyskinesia. Psychiatry Res 26:19–28

    PubMed  CAS  Google Scholar 

  • Lindström LH, Widerlöv E, Gunne LM, Wahlström A, Terenius L (1978) Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states. Acta Psychiatr Scand 57:153–164

    PubMed  Google Scholar 

  • Lindström LH, Nyberg F, Terenius L, Bauer K, Besev G, Gunne LM, Lyrenäs S, Willdeck-Lund G, Lindberg B (1984) CSF and plasma β-casomorphin-like opioid peptides in postpartum psychosis. Am J Psychiatry 141:1059–1066

    PubMed  Google Scholar 

  • Lindström LH, Besev G, Gunne LM, Terenius L (1986) CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolities. Psychiatry Res 19:93–100

    PubMed  Google Scholar 

  • Lo CW, Wen HL, Ho WKK (1983) Cerebrospinal fluid (Met5) enkephalin level in schizophrenics during treatment with naloxone. Eur J Pharmacol 92:77–81

    PubMed  CAS  Google Scholar 

  • Maggio CA, Presta E, Bracco EF, Vasselli JR, Kissileff HR, Pfohl DN, Hashim SA (1985) Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res Bull 14:657–661

    PubMed  CAS  Google Scholar 

  • Malcolm R, O’Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C (1985) A controlled trial of naltrexone in obese humans. Int J Obes 9:437–353

    Google Scholar 

  • Malcolm R, O’Neil PM, von JM, Dickerson PC (1987) Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry 22:710–716

    PubMed  CAS  Google Scholar 

  • Manchanda R, Hirsch SR (1981) (Des-Tyr1)-γ-endorphin in the treatment of schizophrenia. Psychol Med 11:401–404

    Google Scholar 

  • Matthews J, Akil H, Greden J, Charney D (1986) β-Endorphin/β-lipotropin immunoreactivity in endogenous depression. Arch Gen Psychiatry 43:374–381

    PubMed  CAS  Google Scholar 

  • Matussek N, Hoehe M (1989) Investigations with the specific μ-opiate receptor agonist fentanyl in depressive patients: growth hormone, prolactin, cortisol, noradrenaline and euphoric responses. Neuropsychobiology 21:1–8

    PubMed  CAS  Google Scholar 

  • Meador-Woodruff JH, Haskett RF, Grunhaus L, Akil H, Watson SJ, Greden JF (1987) Postdexamethasone plasma cortisol and β-endorphin levels in depression: relationship to severity of illness. Biol Psychiatry 22: 1137–1150

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Busch DA, Tricou BJ, Robertson A (1982) Effect of (des-tyr)-gammaendorphin in schizophrenia. Psychiatry Res 6:313–326

    PubMed  CAS  Google Scholar 

  • Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK (1979) Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 3:231–236

    Google Scholar 

  • Misiaszek J, Cork RC, Hameroff SR, Finley J, Weiss JL (1984) The effect of electroconvulsive therapy on plasma β-endorphin. Biol Psychiatry 19:451–455

    PubMed  CAS  Google Scholar 

  • Mitchell JE, Laine DE, Morley JE, Levine AS (1986) Naloxone but not CCK-8 may attenuate binge-eating in patients with the bulimia syndrome. Biol Psychiatry 21:1399–1406

    PubMed  CAS  Google Scholar 

  • Mitchell JE, Levine AS, Hatsukami D, Gannon M, Pfohl D (1987) High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22:35–42

    PubMed  CAS  Google Scholar 

  • Montgomery SA, Green M, Rimon R, Heikkila L, Foresström R, Hirsch SR, Hallström C, Hippius H, Naber D, Khan MC, Sitsen JMA (1990) Inadequate treatment response to des-enkephalin-γ-endorphin compared with thioridazine and placebo in schizophrenia. Acta Psychiatr Scand (in press)

    Google Scholar 

  • Mosnaim AD, Wolf ME (1988) Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia. J Clin Psychopharmacol 8:S27-S30

    Google Scholar 

  • Murburg MM, Paly D, Wilkinson CW, Veith RC, Malas KL, Dorsa DM (1986) Haloperidol increases plasma β-endorphin-like immunoreactivity and cortisol in normal human males. Life Sci 39:373–381

    PubMed  CAS  Google Scholar 

  • Musacchio JM (1990) The psychotomimetic effects of opiates and the σ receptor. Neuropsychopharmacology 3: 191–200

    PubMed  CAS  Google Scholar 

  • Naber D (1988) Clinical relevance of endorphins in psychiatry. Prog Neuropsychopharmacol Biol Psychiatry 12:S119-S135

    Google Scholar 

  • Naber D, Bullinger M (1985) Neuroendocrine and psychological variables relating to post-operative psychosis after open-heart surgery. Psycho neuroendocrinology 10:315–324

    CAS  Google Scholar 

  • Naber D, Jungkunz G (1986) Opiate receptor sensitivity in depressed patients before and after clomipramine treatment. J Affective Disord 11:59–62

    CAS  Google Scholar 

  • Naber D, Leibl K (1983) Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients. Pharmacopsychiatry 16:43–45

    CAS  Google Scholar 

  • Naber D, Pickar D, Post RM, Van Kammen DP, Waters RN, Ballenger JC, Goodwin FK, Bunney WE (1981) Endogenous opioid activity and β-endorphin immunoreactivity in CSF of psychiatric patient and normal volunteers. Am J Psychiatry 138:1457–1462

    PubMed  CAS  Google Scholar 

  • Naber D, Munch U, Wissmann J, Grosse R, Ritt R, Welter D (1983) Naloxone treatment for 5 days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist. Acta Psychiatr Scand 67:265–271

    PubMed  CAS  Google Scholar 

  • Naber D, Nedopil N, Eben E (1984) No correlation between neuroleptic-induced increase of β-endorphin serum level and therapeutic efficacy in schizophrenia. Br J Psychiatry 144:651–653

    PubMed  CAS  Google Scholar 

  • Naber D, Albus M, Bürke H, Müller-Spahn F, Munch U, Reinertshofer T, Wissmann J, Ackenheil M (1985) Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology. Psychiatry Res 16:207–219

    PubMed  CAS  Google Scholar 

  • Nappi G, Sinforiani E, Martignoni E, Petraglia F, Facchinetti F, Rossi F, Genazzani AR (1988) Aging brain and dementias: changes in central opioids. Eur Neurol 28:217–220

    PubMed  CAS  Google Scholar 

  • Newnham JP, Dennet PM, Ferron SA, Tomlion S, Legg C, Bourne GL, Rees LH (1984) A study of the relationships between circulating β-endorphin-like immunoreactivity and postpartum “blues”. Clin Endocrinol (Oxf) 20:169–177

    CAS  Google Scholar 

  • Norman TR, Piperoglou M, McIntyre IM, Lynch C, Burrows GD (1987) Plasma immunoreactivity β-endorphin in dexamethasone suppressors and non-suppressors of cortisol. J Affective Disord 12:233–239

    CAS  Google Scholar 

  • Owen F, Bourne RC, Poulter M, Crow TJ, Paterson SJ, Kosterlitz HW (1985) Tritiated etorphine and naloxone binding to opioid receptors in caudate nucleus in schizophrenia. Br J Psychiatry 146:507–509

    PubMed  CAS  Google Scholar 

  • Panksepp J, Sahley TL (1987) Possible brain opioid involvement in disrupted social intent and language development of autism In: Schopler E, Mesibov GB (eds) Neurobiological issues in autism. Plenum, New York, pp 357–372

    Google Scholar 

  • Pethö B, Graf L, Karczag I, Bitter I, Tolna J, Baraczka K, Li CH (1981) β-Endorphin and schizophrenia Lancet 1:212–213

    PubMed  Google Scholar 

  • Pfaus JG, Gorzalka BB (1986) Opioids and sexual behavior. Neurosci Biobehav Rev 11:1–34

    Google Scholar 

  • Pfeiffer A, Herz A (1984) Endocrine actions of opioids. Horm Metab Res 16:386–397

    PubMed  CAS  Google Scholar 

  • Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by κ-opiate receptors. Science 233:774–776

    PubMed  CAS  Google Scholar 

  • Pickar D, Cutler NR, Naber D, Post RM, Pert C, Bunney WE (1980) Plasma opioid activity in manic-depressive illness. Lancet 1:937

    PubMed  CAS  Google Scholar 

  • Pickar D, Davis GC, Schulz SC, Extein I, Wagner R, Naber D, Gold PW, Van Kammen DP, Goodwin FK, Wyatt RJ, Li CH, Bunney WE (1981) Behavioral and biological effects of acute β-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry 138:160–166

    PubMed  CAS  Google Scholar 

  • Pickar D, Cohen MR, Naber D, Cohen RM (1982a) Clinical studies of the endogenous opioid system. Biol Psychiatry 17:1243–1276

    PubMed  CAS  Google Scholar 

  • Pickar D, Vartanian F, Bunney WE, Maier HP, Gastpar MT, Prakash R, Sethi BB, Lidemann R, Belyaev BS, Tsutsulkovskaja MVA, Jungkunz G, Nedopil N, Verhoeven W, Van Praag H (1982b) Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization collaborative study. Arch Gen Psychiatry 39:313–319

    PubMed  CAS  Google Scholar 

  • Pickar D, Bunney WE Jr, Douillet P, Sethi BB, Sharma M, Vartanian ME, Lideman RP, Naber D, Leibl K, Yamashita I, Koyama T, Verhoeven WMA, Vartanian F, Morozov PV, Khac TN (1989) Repeated naloxone administration in schizophrenia: a phase II World Health Organization study. Biol Psychiatry 25:440–448

    PubMed  CAS  Google Scholar 

  • Pögün S, Demirgören S, Kutay FZ, Hariri N, Karaali H (1988) Nalosone binding in the frontal cortex of postmortem human brain. Prog Neuropsychopharmacol Biol Psychiatry 13:167–171

    Google Scholar 

  • Reisine TD, Rossor M, Spokes E, Iversen LL, Yamamura HI (1980) Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. In: Pepeu G, Kuhar MJ, Enna SJ (eds) Receptors for neurotransmitters and peptide hormones. Raven, New York, pp 443–445.

    Google Scholar 

  • Richardson JS, Zaleski WA (1983) Naloxone and self-mutilation. Biol Psychiatry 18:99–101

    PubMed  CAS  Google Scholar 

  • Rimon R, Terenius L, Kampman R (1980) Cerebrospinal fluid endorphins in schizophrenia. Acta Psychiat Scand 61:395–403

    PubMed  CAS  Google Scholar 

  • Rimon R, Terenius L, Averbuch I, Belmaker RH (1983) High-dose haloperidol increases CSF opioid activity in patients With chronic schizophrenia. Pharmacopsychiatry 16:9–12

    CAS  Google Scholar 

  • Risch SC (1982) β-Endorphin hypersecretion in depression: possible cholinergic mechanism. Biol Psychiatry 17: 1071–1079

    PubMed  CAS  Google Scholar 

  • Robertson AG, Jackman H, Meltzer HY (1984) Prolactin response to morphine in depression. Psychiatry Res 11:353–364

    PubMed  CAS  Google Scholar 

  • Ross M, Berger PA, Goldstein A (1979) Plasma β-endorphin immunoreactivity in schizophrenia. Science 205:1163–1164

    PubMed  CAS  Google Scholar 

  • Rupprecht R, Lesch K-P, Müller U, Beck G, Beckmann H, Schulte HM (1989) Blunted adrenocorticotropin but normal β-endorphin release after human corticotropin-releasing hormone administration in depression. J Clin Endocrinol Metab 69:600–603

    PubMed  CAS  Google Scholar 

  • Sandman CA, Barron JL, Crinella FM, Donnelly JF (1987) Influence of naloxone on brain and behavior of a self-injurious woman. Biol Psychiatry 22:899–906

    PubMed  CAS  Google Scholar 

  • Scarone S, Gambint O, Calabrese G, Sacerdote P, Bruni M, Carucci M, Panerai AE (1990) Asymmetrical distribution of β-endorphin in cerebral hemispheres of suicides: preliminary data. Psychiatry Res 32:159–166

    PubMed  CAS  Google Scholar 

  • Schoemaker H, Davis TP (1984) Differential in vitro metabolism of β-endorphin in schizophrenia. Peptides 5:1049–1054

    PubMed  CAS  Google Scholar 

  • Schull J, Kaplan H, O’Brien CP (1981) Naloxone can alter experimental pain and mood in humans. Physiol Psychol 9:245–250

    CAS  Google Scholar 

  • Schulz SC, van Kammen DP, Balow JE, Flye MW, Bunney WE (1981) Dialysis in schizophrenia: a double-blind evaluation. Science 211:1066–1068

    PubMed  CAS  Google Scholar 

  • Sethi BB, Prakasch R (1981) A study of naloxone with schizophrenic and manic patients. Br J Psychiatry 138:501–503

    PubMed  CAS  Google Scholar 

  • Sulkava R, Erkinjutti T, Laatikainen T (1985) CSF β-endorphin and β-lipotropin in Alzheimer’s disease and multi-infarct dementia. Neurology 35: 1057–1058

    PubMed  CAS  Google Scholar 

  • Tamminga CA, Tighe PJ, Chase TN, DeFraites EG, Schaffer MH (1981) Destyrosine- gamma-endorphin administration in chronic schizophrenics. Arch Gen Psychiatry 38:167–168

    PubMed  CAS  Google Scholar 

  • Terenius L, Wahlstrom A, Lindström L, Widerlöv E (1976) Increased CSF levels of endorphins in chronic psychosis. Neurosci Lett 3:157–162

    PubMed  CAS  Google Scholar 

  • Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121–137

    PubMed  CAS  Google Scholar 

  • Trenchard E, Silverstone T (1983) Naloxone reduces the food intake of normal human volunteers. Appetite 4:43–50

    PubMed  CAS  Google Scholar 

  • Tulenheimo A, Laatikainen T, Salminen K (1987) Plasma β-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynecol 94:26–29

    CAS  Google Scholar 

  • Van Praag HM, Verhoeven WMA, Van Ree JM, De Wied D (1982) The treatment of schizophrenic psychoses with gamma-type endorphins. Biol Psychiatry 17: 83–98

    PubMed  Google Scholar 

  • Verhoeven WMA, Van Praag HM, Van Ree JM, De Wied D (1979) Improvement of schizophrenic patients treated with (des-tyr)-gamma-endorphin (DTγE). Arch Gen Psychiatry 36:294–298

    PubMed  CAS  Google Scholar 

  • Verhoeven WMA, Van Ree JM, Van Bentum AH, Van Praag HM (1982) Antipsychotic properties of des-enkephalin-gamma-endorphin treatment of schizophrenic patients. Arch Gen Psychiatry 39:648–654

    PubMed  CAS  Google Scholar 

  • Verhoeven WMA, Van Praag HM, Van Ree JM (1984) Repeated naloxone administration in schizophrenia. Psychiatry Res 12:297–312

    PubMed  CAS  Google Scholar 

  • Volavka J, Mallya A, Baig S, Perez-Cruet J (1977) Naloxone in chronic schizophrenia. Science 196:11227–11228

    Google Scholar 

  • Watson SJ, Berger PA, Akil H, Mills MJ, Barchas JD (1978) Effects of naloxone on schizophrenia: reduction in hallucinations in a sub-population of subjects. Science 201:73–75

    PubMed  CAS  Google Scholar 

  • Weizman A, Gil-Ad I, Grupper D, Tyano S, Laron Z (1987) The effect of acute and repeated electroconvulsive treatment on plasma β-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients. Psychopharmacology 93:122–126

    PubMed  CAS  Google Scholar 

  • Weizman R, Gil-Ad I, Hermesh H, Munitz H, Laron Z (1990) Immunoreactive β-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuropharmacol 13:297–302.

    PubMed  CAS  Google Scholar 

  • Wen HL, Lo CW, Ho WKK (1983) Met-enkephalin level in the cerebrospinal fluid of schizophrenic patients. Clin Chim Acta 128:367–371

    PubMed  CAS  Google Scholar 

  • Wiegant VM, Verhoef CJ, Burbach JPH, De Wied D (1988) Increased concentration of α- and γ-endorphin in post mortem hypothalamic tissue of schizophrenic patients. Life Sci 42: 1733–1742

    PubMed  CAS  Google Scholar 

  • Wildman J, Krüger A, Schmole M, Niemann J, Matthaei H (1986) Increase of circulating beta-endorphin-like immuno-activity, correlates wtih the change in feeling of pleasantness after running. Life Sci 38:997–1003

    Google Scholar 

  • Wolkowitz OM, Doran AR, Cohen MR, Cohen RM, Wise TN, Pickar D (1985) Effect of naloxone on food consumption in obesity. N Engl J Med 313:327

    PubMed  CAS  Google Scholar 

  • Wolkowitz OM, Doran AR, Breier A, Cohen MR, Pickar D (1986) Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. Biol Psychiatry 21:366–373

    PubMed  CAS  Google Scholar 

  • Young EA, Watson SJ, Kotun J, Haskett RF, Grunhaus L, Murphy-Weinberg V, Vale W, Rivier J, Akil H (1990) β-Lipotropin-β-endorphin response to lowdose ovine corticotropin releasing factor in endogenous depression. Arch Gen Psychiatry 47:449–457

    PubMed  CAS  Google Scholar 

  • Zech M, Bogerts B (1985) Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. Acta Neuropathol (Berl) 68:32–38

    CAS  Google Scholar 

  • Zhang AZ, Zhou GZ, Xi GF, Gu NF, Xia ZY, Yao JL (1985) Lower CFS level of dynorphin (1–8) immunoreactivity in schizophrenic patients. Neuropeptides 5:553–556

    PubMed  Google Scholar 

  • Zis AP, Haskett RF, Albala AA, Carroll BJ, Lohr NE (1985a) Prolactin response to morphine in depression. Biol Psychiatry 20:287–292

    PubMed  CAS  Google Scholar 

  • Zis AP, Haskett RF, Albala AA, Carroll BJ, Lohr NE (1985b) Opioid regulation of hypothalamic-pituitary adrenal function in depression. Arch Gen Psychiatry 42:383–386

    PubMed  CAS  Google Scholar 

  • Zis AP, Haskett RF, Albala AA, Carroll BJ, Lohr NE (1985c) Cortisol escape from morphine suppression. Psychiatry Res 15:91–95

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Neuropharmakologie, Max-Planck-Institut für Psychiatrie, Am Klopferspitz 18, W-8033, Martinsried, Germany

    Albert Herz

  2. Mental Health Research Institute, School of Medicine, University of Michigan, 205 Zina Pitcher, 48109, Ann Arbor, MI, USA

    Huda Akil

  3. Medical Center, School of Medicine, New York University, 550 First Avenue, 10016, New York, NY, USA

    Eric J. Simon

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Naber, D. (1993). Opioids in the Etiology and Treatment of Psychiatric Disorders. In: Herz, A., Akil, H., Simon, E.J. (eds) Opioids II. Handbook of Experimental Pharmacology, vol 104 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77540-6_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77540-6_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77542-0

  • Online ISBN: 978-3-642-77540-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation